LOS ANGELES – At the American Academy of Neurology (AAN) annual meeting this week, Walter Koroshetz pointed out two causes of the opioid epidemic that are obvious in one sense. But ending the opioid epidemic will require figuring out a way to address the relationship between them.

Astrazeneca plc spinout Corvidia Therapeutics Inc.'s $60 million in series B money should let the company "expand into earlier stages of chronic kidney disease [CKD] and apply our scientific approach further into areas of heart failure," CEO Marc de Garidel told BioWorld.

The U.S. Supreme Court closed the door Tuesday on hopes of a constitutional escape from inter partes review (IPR) challenges of valuable patents that are the foundation for biotech and med tech.

After hours of trying to get their minds around mismatched study results and data that didn't lend themselves to the questions the FDA was asking, members of the Arthritis Advisory Committee voted 10-5 Monday to recommend approval of a 2-mg dose of Eli Lilly and Co.'s baricitinib, while rejecting a 4-mg dose in a reverse vote of 5-10.

- Shire digs Takeda's remix: Revised offer worth $64B
- Kidney disease drug lands FDA approval after initial rejection
- Corvidia's $60M series B fuels CKD, heart research; phase II trial reports soon
- Wanted: More biotech listings for Hong Kong as new rules set to go into effect next week
- Fresh off humbling career move, former Alexion exec helms startup Rallybio
- China's money hose keeping the biotech sector well-watered
- Alphamab's bispecific antibody gets clinical approval in China
- Tocagen licenses rights to Apollobio for cancer immunotherapy in China
- Aussie biotechs to benefit from strategic intervention partnering program
- With first WHO pre-qualification, Pakistani gene...


The outlook for the future of hepatitis C virus (HCV) treatment seemed to split into two distinct camps at the 2018 International Liver Congress (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), held this month in Paris.
A study has identified common genetic variants in the Chinese population contributing to the risk of developing Alzheimer's disease (AD) that possibly exert functional effects through the immune system, which could have important implications for AD management.
The search continues for promising biomarkers and effective disease-modifying therapies for AD. The current drug development approaches mainly target the disease's hallmark pathology of amyloid-beta (Abeta) protein accumulation in the brain leading to Abeta plaque deposition.
READ MORE »- G proteins join kinases as druggable cancer targets »
- Antisense oligonucleotide skips exon 53 in DMD patients »
- Study finds silver lining for meningeal damage »
- New approach breaches 'firewall' between GWAS, effectors »
- Genetic Alzheimer’s risk factor repaired in human brain cells »
- Platelets, antibodies form anaphylaxis alliance »
- Compound accelerates post-stroke motor function recovery »
- Researchers disagree on whether adults make new brain cells »
- Rabies virus vector gives immune system second chance at fighting West Nile »

- If no one reads it, what’s the purpose of a drug label?March 29, 2018 | 11:29 PM | Posted by: Mari Serebrov
- The opioid crisis: A venture in need of a GAIN?February 16, 2018 | 6:01 PM | Posted by: Jennifer Boggs
- Real-world optics of biopharma price hikesFebruary 03, 2018 | 12:11 AM | Posted by: Mari Serebrov
- Science for the season: BioWorld’s 11th annual Holiday Gift GuideDecember 01, 2017 | 12:54 AM | Posted by: Marie Powers
- Drug quality from a patient’s perspectiveSeptember 10, 2017 | 2:06 PM | Posted by: Mari Serebrov
Partners in Focus
Cast Your Vote
Reproduction, reposting content is strictly prohibited.